1. Scrip
  2. >>R&D
  3. >>Clinical Trials

High-Dose Semaglutide Data A Mixed Bag For Novo Nordisk

 
• By Joseph Haas

Semaglutide 7.2mg bests placebo for weight loss at 72 weeks, but with efficacy lower than seen with Novo Nordisk’s CagriSema or Lilly’s Zepbound.

Female hands holding an insulin pen. Ozempic Insulin injection pen or insulin cartridge pen for diabetics
High-dose semaglutide meets endpoint in Phase III, but doesn't beat Zepbound, CagriSema (Shutterstock)

Novo Nordisk reported a successful Phase IIIb result for high-dose semaglutide in obese adults on 17 January, but analysts pointed out that while the data topped the weight loss demonstrated by the drug’s marketed 2.4mg dose of Wegovy, it fell short of the efficacy produced by Lilly’s Zepbound (tirzepatide) at the same time point in a Phase III study.

Key Takeaways
  • Novo Nordisk demonstrated that 7.2mg weekly of semaglutide, three times the highest dose approved for Wegovy, produced average weight loss of 20.7% at 72 weeks.

In the 1,407-patient STEP UP study, semaglutide 7.2mg weekly injection yielded a 20.7% weight loss from baseline at 72 weeks, which Leerink Partners analyst David Risinger noted was not superior...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapy Areas

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.